NewGenIvf Group

NewGenIvf Group EBITDA per Share

The EBITDA per Share of NewGenIvf Group (NIVF) as of Oct 20, 2026 is -658.07 USD. In the previous year, EBITDA per Share was -11,600.00 USD — a change of -94.33% (higher).

EBITDA per Share

-658.07USD

YoY

-94.33%

Last updated:

EBITDA per Share of NewGenIvf Group is 2025 -658.07 USD. EBITDA per Share of NewGenIvf Group was 2024 -11,600.00 USD. It decreases by -94.33% higher compared to the previous year.

The NewGenIvf Group EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
6.83 USD
Jan 1, 2022
13.70 USD
Jan 1, 2023
-0.68 USD
Jan 1, 2024
-11,600.00 USD
Jan 1, 2025
-658.07 USD
The NewGenIvf Group EBITDA per Share history
YEAREBITDA per ShareYoY
-658.07USD-94.33%
-11,600.00USD+1.71 M%
-0.68USD-104.94%
13.70USD+100.60%
6.83USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NewGenIvf Group Stock analysis

What does NewGenIvf Group do? NewGenIvf Group Ltd provides comprehensive fertility services across Asia, including IVF, ICSI, IUI, and MRT techniques. The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering treatments such as embryo transfer, chromosome screening, egg freezing, and sperm aspiration. Patients seeking assisted reproductive technology services, including those requiring third-party egg donation or surrogacy, are the primary customers. The firm generates revenue through direct patient fees for these specialized fertility treatments and related services across its Asian clinics. The company's service portfolio includes Mitochondrial Replacement Therapy In Reproductive, Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), semen analysis, and sperm extraction procedures. These services are delivered through clinics in Thailand, Cambodia, and Kyrgyzstan, targeting individuals and couples facing infertility challenges. Revenue is derived from the full range of fertility treatments provided at these locations. NewGenIvf Group Ltd's offerings encompass full-spectrum infertility care, including egg and sperm donation programs and surrogacy services within compliant jurisdictions. The clinics serve patients requiring advanced reproductive technologies, with MRT being a specialized service involving third-party egg contribution. The business model relies on direct patient payments for all treatment packages and ancillary services provided at its Asian locations. NewGenIvf Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NewGenIvf Group stock

EBITDA per Share of NewGenIvf Group is -658.07 USD in 2025.

EBITDA per Share of NewGenIvf Group changed from -11,600.00 USD to -658.07 USD, representing a -94.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share NewGenIvf Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — NewGenIvf Group

All Key Metrics — NewGenIvf Group